All News
European Research Council has awarded a Proof of Concept Grant to Institute of Bioengineering of Catalonia and their OrthoBots project, to study the treatment of joint diseases using nanorobots to deliver nanoparticle based therapy to synovial tissues https://t.co/JmYQ1727rf https://t.co/k5uZoSwJPo
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Community-Acquired Pneumonia (CAP)
https://t.co/geb8y2AK26 https://t.co/cB3y5vQoz1
Dr. John Cush RheumNow ( View Tweet)
Urticarial vasculitis - rare autoimmune dz w/ persistent edematous papules & plaques lasting >24 hrs, w/ systemic Sxs (joint pain, fever). Long-lasting skin lesions tend to leave a bruiselike look. Requires Bx show leukocytoclasticl vasculitis https://t.co/cFWrntrlMw https://t.co/JPkh5FVNo3
Links:
Dr. John Cush RheumNow ( View Tweet)
PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?
Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders.
https://t.co/Slnq68YQgh https://t.co/nCYswGmlCk
Dr. John Cush RheumNow ( View Tweet)
IV zoledronic acid (ZA) does not prevent future knee replacement (TKR) in symptomatic knee OA without severe joint space narrowing (JSN). In 222 Knee OA pts, after 7 yrs F/U, ZA had more TKR (39% vs 30%; HR 4.2' 1.2-14.7) https://t.co/2cGeqz2Rwu https://t.co/1UiODwQiK6
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Dead Words Eulogy
https://t.co/kmgWJDMigE https://t.co/raZvkGW4vv
Dr. John Cush RheumNow ( View Tweet)
CT angio in 75 pts w/ Takayasu arteritis (40 w/ cDMARDs, 35 biologics) showed reduced arterial thickness in 73% (31% w/ >25% decr in wall thickness). 1st immunosuppressives (p= 0.012) & bDMARDs(p= 0.026) reduced art. wall thickness (relative to cDMARDs) https://t.co/16eGmgVoWr https://t.co/AyNyT7FsYZ
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Recommendations on Reproductive Health
https://t.co/QuXQlpQv8O https://t.co/nHC7LOLLl8
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI?
https://t.co/J4aE4jxNb0 https://t.co/b6axwp4Tuw
Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
https://t.co/iccSFuAogX https://t.co/ORzwvDKqVo
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
https://t.co/46g8ek286u https://t.co/FEFq4vkiPk
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of Amyloidosis
The New England Journal of Medicine has published a review of systemic amyloidosis.
https://t.co/qtbdPrlKnj https://t.co/wcqvRAauWC
Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial.
Would love to eventually see:
- H2H comparative effect vs toci, secukinumab
- structural outcomes
- long-term safety
#EULAR2024
Dr. John Cush RheumNow ( View Tweet)
Review of Amyloidosis
The New England Journal of Medicine has published a review of systemic amyloidosis.
https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr
Dr. John Cush RheumNow ( View Tweet)
How do you manage new progressive ILD?
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn
Dr. John Cush RheumNow ( View Tweet)
Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA
Dr. John Cush RheumNow ( View Tweet)
Digital Rheumatology
Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
https://t.co/9twSiXYL3N https://t.co/9vz77SrVLt
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Autoimmune Dz (AID) & myelodysplastic syndrome (MDS) finds AIDs found in 17.5% of MDS pts. With AID, MDS mortality rates ranged 15.3-67%. Why this relationship exists is unclear. https://t.co/SZNH8v2CIT https://t.co/QTGiqUCqqs
Dr. John Cush RheumNow ( View Tweet)
ChatGPT in Rheumatology and Qualitative Research
Dr. Bella Mehta discusses abstract OP0158 presented at Eular 2024 in Vienna, Austria.
https://t.co/2EGLJdK2Pl https://t.co/AaRFqyo6jq
Dr. John Cush RheumNow ( View Tweet)
